Core Insights - Akari Therapeutics, Plc is a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADCs) for cancer treatment [2][7] - The company has launched a portal on the Webull Corporate Connect Service platform to enhance communication and transparency with shareholders and investors [3][4] Company Overview - Akari Therapeutics utilizes an innovative ADC discovery platform to create novel bi-functional ADC candidates aimed at targeting various cancers [7] - The lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells and employs a proprietary linker to deliver a novel PH1 payload directly into tumors [7] - AKTX-101 is designed to induce tumor-specific cell death while minimizing off-target toxicity, potentially overcoming limitations of current ADCs [7] Product Development - In preclinical studies, AKTX-101 has demonstrated superior activity, prolonged survival, reduced resistance, and better tolerability compared to existing treatments [7] - The candidate has shown potential for synergy with checkpoint inhibitors and has resulted in prolonged survival in preclinical models [7] - The company is actively generating validating data on its novel payloads to advance its product pipeline [7] Communication Strategy - The addition of the Webull platform is part of the company's strategy to build market awareness and increase visibility among investors [4] - The platform will facilitate the release of corporate content, including news, earnings reports, and product updates [3][4]
Akari Therapeutics Joins Webull Corporate Connect Service Platform